期刊文献+

石榴籽油对去卵巢大鼠骨质代谢的影响 被引量:3

下载PDF
导出
摘要 目的探讨石榴籽油对去卵巢大鼠骨质代谢的影响。方法 50只3月龄SPF级雌性SD大鼠随机分为假手术组、去卵巢组、己烯雌酚组、低石榴籽油组和高石榴籽油组,每组10只。假手术组保留卵巢,其余组则将双侧卵巢去除,已烯雌酚组每天用100μg/kg己烯雌酚灌胃,低石榴籽油组和高石榴籽油组每天分别给予石榴籽油0.95 g/kg和1.27 g/kg剂量灌胃。对大鼠血清钙(Ca)、磷(P)含量以及碱性磷酸酶活性(ALP)、超氧化物歧化酶(SOD)和丙二醛(MDA)水平进行检测,并对下颌骨、股骨中段和远心端骨密度进行检测。结果与去卵巢组相比,己烯雌酚组、低石榴籽油组和高石榴籽油组大鼠血清Ca、P含量及ALP活性均降低,低石榴籽油组和高石榴籽油组大鼠血清SOD水平升高,而MDA水平降低(P<0.05);与己烯雌酚组相比,低石榴籽油组大鼠血清Ca、P和SOD含量升高,而MDA含量降低,高石榴籽油组大鼠血清SOD含量升高,而MDA降低(P<0.05);与去卵巢组相比,己烯雌酚组、低石榴籽油组和高石榴籽油组大鼠下颌骨、股骨中点和股骨远端骨密度均升高(P<0.05)。结论补充石榴籽油可有效降低去卵巢大鼠骨质转化活性,抑制骨密度降低,而这种作用可能与石榴籽油雌激素作用及抗氧化作用有关。
出处 《中国老年学杂志》 CAS CSCD 北大核心 2016年第20期4956-4958,共3页 Chinese Journal of Gerontology
基金 内蒙古自治区自然科学基金项目(2014MS0812) 包头市社会发展科技支撑项目(2014S2003-5-12) 内蒙古医疗卫生科研计划项目(201302101)
  • 相关文献

参考文献11

  • 1Tian J,Xu XJ,Shen L,et al.Association of serum Dkk-1 levels withβ-catenin in patients with postmenopausal osteoporosis[J].J Huazhong Univ Sci Technolog Med Sci,2015;35(2):212-8.
  • 2Min YK.Update on denosumab treatment in postmenopausal women with osteoporosis[J].Endocrinol Metab(Seoul),2015;30(1):19-26.
  • 3Miyauchi Y,Sato Y,Kobayashi T,et al.HIF1αis required for osteoclast activation by estrogen deficiency in postmenopausal osteoporosis[J].Proc Natl Acad Sci U S A,2013;110(41):16568-73.
  • 4Tran HN,Bae SY,Song BH,et al.Pomegranate(Punica granatum)seed linolenic acid isomers:concentration-dependent modulation of estrogen receptor activity[J].Endocr Res,2010;35(1):1-16.
  • 5Bernabei R,Martone AM,Ortolani E,et al.Screening,diagnosis and treatment of osteoporosis:a brief review[J].Clin Cases Miner Bone Metab,2014;11(3):201-7.
  • 6Golob AL,Laya MB.Osteoporosis:screening,prevention,and management[J].Med Clin North Am,2015;99(3):587-606.
  • 7Palacios S,Currie H,Mikkola TS,et al.Perspective on prescribing conjugated estrogens/bazedoxifene for estrogen-deficiency symptoms of menopause:A practical guide[J].Maturitas,2015;80(4):435-40.
  • 8Hegazy SK.Evaluation of the anti-osteoporotic effects of metformin and sitagliptin in postmenopausal diabetic women[J].J Bone Miner Metab,2015;33(2):207-12.
  • 9Liu Y,Li M,Zhou PR,Xing XP,Xia WB,Xu L,Liu H J,Zhang ZL,LiaoEY,Chen DC,Liu J,Tao TZ,Wu W.Association of farnesyl diphosphate synthase polymorphisms and response to alendronate treatment in Chinese postmenopausal women with osteoporosis[J].Chinese Medical Journal,2014(4):662-668. 被引量:16
  • 10Manolagas SC.From estrogen-centric to aging and oxidative stress:a revised perspective of the pathogenesis of osteoporosis[J].Endocr Rev,2010;31(3):266-300.

二级参考文献26

  • 1Favus MJ. Bisphosphonates for osteoporosis. N Engl J Med 2010; 363:2027-2035.
  • 2Rees M. Management of the menopause:integrated health-care pathway for the menopausal woman. Menopause Int 2011; 17:50-54.
  • 3Palacios S,Brincat M,Erel CT,Gambacciani M,Lambrinoudaki I,Moen MH,et al. EMAS clinical guide:selective estrogen receptor modulators for postmenopausal osteoporosis. Maturitas 2012; 71:194-198.
  • 4Meunier PJ,Roux C,Seeman E,Ortolani S,Badurski JE,Spector TD,et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004; 350:459-468.
  • 5Neer RM,Arnaud CD,Zanchetta JR,Prince R,Gaich GA,Reginster JY,et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344:1434-1441.
  • 6Bergstrom JD,Bostedor RG,Masarachia P J,Reszka AA,Rodan G. Alendronate is a specific,nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys 2000; 373:231-241.
  • 7Beukelman T,Saag KG,Curtis JR,Kilgore ML,Pisu M. Costeffectiveness of multifaceted evidence implementation programs for the prevention of glucocorticoid-induced osteoporosis. Osteoporos Int 2010; 21:1573-1584.
  • 8Palomba S,Numis FG,Mossetti G,Rendina D,Vuotto P,Russo T,et al. Effectiveness of alendronate treatment in postmenopausal women with osteoporosis:relationship with BsmI vitamin D receptor genotypes. Clin Endocrinol (Oxf) 2003; 58:365-371.
  • 9Ralston SH. Genetic control of susceptibility to osteoporosis. J Clin Endocrinol Metab 2002; 87:2460-2466.
  • 10Fang Y,Rivadeneira F,van Meurs JB,Pols HA,Ioannidis JP,Uitterlinden AG. Vitamin D receptor gene BsmI and TaqI polymorphisms and fracture risk:a meta-analysis. Bone 2006; 39:938-945.

共引文献15

同被引文献52

引证文献3

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部